Skip to main content
Premium Trial:

Request an Annual Quote

William Blair Initiates Coverage of Illumina with 'Outperform' Rating

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm William Blair said today it has initiated coverage of Illumina's stock, giving it an "outperform" rating.

It also gave San Diego-based Illumina an "aggressive growth" company profile. Amanda Murphy, an analyst at William Blair, estimated a $1.06 earnings per share price for 2010, a $1.46 EPS for 2011, and a $1.93 EPS for 2012.

In a statement, Murphy took note of the HiSeq next-generation sequencing platform introduced a year ago. The system offers the highest throughput of any next-gen sequencer, she said, adding that Illumina is "by far" the market leader in the space with a 60 percent share.

"We expect the HiSeq product cycle to fuel 30 percent earnings growth through 2012 as instrument sales translate into higher-margin consumable revenue and through margin improvements as Illumina optimizes the HiSeq platform," Murphy said.

In Friday afternoon trade on the Nasdaq, shares of Illumina were down 2 percent at $65.52.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.